Use of anti-VEGF adjuvant therapy in cancer: challenges and rationale

Mano, 2008, Colon cancer: update on adjuvant therapy, Clin. Colorectal Cancer, 7, 178, 10.3816/CCC.2008.n.023 Fisher, 1981, Treatment of primary breast cancer with chemotherapy and tamoxifen, N. Engl. J. Med., 305, 1, 10.1056/NEJM198107023050101 Romond, 2005, Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer, N. Engl. J. Med., 353, 1673, 10.1056/NEJMoa052122 Folkman, 1971, Tumor angiogenesis: therapeutic implications, N. Engl. J. Med., 285, 1182, 10.1056/NEJM197111182852108 Hurwitz, 2004, Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer, N. Engl. J. Med., 350, 2335, 10.1056/NEJMoa032691 Giantonio, 2007, Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200, J. Clin. Oncol., 25, 1539, 10.1200/JCO.2006.09.6305 Sandler, 2006, Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer, N. Engl. J. Med., 355, 2542, 10.1056/NEJMoa061884 Miller, 2007, Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer, N. Engl. J. Med., 357, 2666, 10.1056/NEJMoa072113 Friedman, 2009, Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma, J. Clin. Oncol., 27, 4733, 10.1200/JCO.2008.19.8721 Kreisl, 2009, Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma, J. Clin. Oncol., 27, 740, 10.1200/JCO.2008.16.3055 Jenab-Wolcott, 2009, Bevacizumab: current indications and future development for management of solid tumors, Expert Opin. Biol. Ther., 9, 507, 10.1517/14712590902817817 Shih, 2006, Bevacizumab: an angiogenesis inhibitor for the treatment of solid malignancies, Clin. Ther., 28, 1779, 10.1016/j.clinthera.2006.11.015 Bagri, 2009, Neuropilins in tumor biology, Clin. Cancer Res., 15, 1860, 10.1158/1078-0432.CCR-08-0563 Hicklin, 2005, Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis, J. Clin. Oncol., 23, 1011, 10.1200/JCO.2005.06.081 Vredenburgh, 2007, Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma, Clin. Cancer Res., 13, 1253, 10.1158/1078-0432.CCR-06-2309 Numnum, 2006, The use of bevacizumab to palliate symptomatic ascites in patients with refractory ovarian carcinoma, Gynecol. Oncol., 102, 425, 10.1016/j.ygyno.2006.05.018 Chong, 2005, Improving long-term outcomes for patients with liver metastases from colorectal cancer, J. Clin. Oncol., 23, 9063, 10.1200/JCO.2005.04.4669 Ellis, 2005, Surgical resection after downsizing of colorectal liver metastasis in the era of bevacizumab, J. Clin. Oncol., 23, 4853, 10.1200/JCO.2005.23.754 O’Connor, 2009, Quantifying antivascular effects of monoclonal antibodies to vascular endothelial growth factor, Clin. Cancer Res., 15, 6674, 10.1158/1078-0432.CCR-09-0731 Jain, 2005, Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy, Science, 307, 58, 10.1126/science.1104819 Kerbel, 2006, Antiangiogenic therapy: a universal chemosensitization strategy for cancer?, Science, 312, 1171, 10.1126/science.1125950 Teicher, 1996, A systems approach to cancer therapy. (Antioncogenics + standard cytotoxics→mechanism(s) of interaction), Cancer Metastasis Rev., 15, 247, 10.1007/BF00437479 Boucher, 1996, Tumor angiogenesis and interstitial hypertension, Cancer Res., 56, 4264 Nakahara, 2006, Effect of inhibition of vascular endothelial growth factor signaling on distribution of extravasated antibodies in tumors, Cancer Res., 66, 1434, 10.1158/0008-5472.CAN-05-0923 Tong, 2004, Vascular normalization by vascular endothelial growth factor receptor 2 blockade induces a pressure gradient across the vasculature and improves drug penetration in tumors, Cancer Res., 64, 3731, 10.1158/0008-5472.CAN-04-0074 Yuan, 1996, Time-dependent vascular regression and permeability changes in established human tumor xenografts induced by an anti-vascular endothelial growth factor/vascular permeability factor antibody, Proc. Natl. Acad. Sci. U. S. A., 93, 14765, 10.1073/pnas.93.25.14765 Yuan, 1995, Vascular permeability in a human tumor xenograft: molecular size dependence and cutoff size, Cancer Res., 55, 3752 Flessner, 2005, Resistance of tumor interstitial pressure to the penetration of intraperitoneally delivered antibodies into metastatic ovarian tumors, Clin. Cancer Res., 11, 3117, 10.1158/1078-0432.CCR-04-2332 Gerber, 2002, VEGF regulates haematopoietic stem cell survival by an internal autocrine loop mechanism, Nature, 417, 954, 10.1038/nature00821 Bao, 2006, Stem cell-like glioma cells promote tumor angiogenesis through vascular endothelial growth factor, Cancer Res., 66, 7843, 10.1158/0008-5472.CAN-06-1010 Jiang, H. et al. (2010) Low-dose metronomic paclitaxel chemotherapy suppresses breast tumors and metastases in mice. Pathways mediating VEGF-independent tumor angiogenesis. Cancer Invest., doi:10.3109/07357900902744510 Yang, 2004, Expansion of myeloid immune suppressor Gr+CD11b+ cells in tumor-bearing host directly promotes tumor angiogenesis, Cancer Cell, 6, 409, 10.1016/j.ccr.2004.08.031 Shaked, 2006, Therapy-induced acute recruitment of circulating endothelial progenitor cells to tumors, Science, 313, 1785, 10.1126/science.1127592 de Boer, 2009, Micrometastases or isolated tumor cells and the outcome of breast cancer, N. Engl. J. Med., 361, 653, 10.1056/NEJMoa0904832 Jemal, 2008, Cancer statistics, 2008, CA Cancer J. Clin., 58, 71, 10.3322/CA.2007.0010 Bergers, 2003, Tumorigenesis and the angiogenic switch, Nat. Rev. Cancer, 3, 401, 10.1038/nrc1093 Indraccolo, 2006, Interruption of tumor dormancy by a transient angiogenic burst within the tumor microenvironment, Proc. Natl. Acad. Sci. U. S. A., 103, 4216, 10.1073/pnas.0506200103 Almog, 2009, Transcriptional switch of dormant tumors to fast-growing angiogenic phenotype, Cancer Res., 69, 836, 10.1158/0008-5472.CAN-08-2590 Naumov, 2006, A model of human tumor dormancy: an angiogenic switch from the nonangiogenic phenotype, J. Natl. Cancer Inst., 98, 316, 10.1093/jnci/djj068 Mabuchi, 2008, Maintenance treatment with bevacizumab prolongs survival in an in vivo ovarian cancer model, Clin. Cancer Res., 14, 7781, 10.1158/1078-0432.CCR-08-0243 Kolinsky, 2009, In vivo activity of novel capecitabine regimens alone and with bevacizumab and oxaliplatin in colorectal cancer xenograft models, Mol. Cancer Ther., 8, 75, 10.1158/1535-7163.MCT-08-0596 Mathieu, V. et al. (2008) Combining bevacizumab with temozolomide increases the antitumor efficacy of temozolomide in a human glioblastoma orthotopic xenograft model. Neoplasia 10, 1383–1392 Relf, 1997, Cancer Res., 57, 963 Casanovas, 2005, Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors, Cancer Cell, 8, 299, 10.1016/j.ccr.2005.09.005 Holash, 1999, Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF, Science, 284, 1994, 10.1126/science.284.5422.1994 Du, 2008, HIF1alpha induces the recruitment of bone marrow-derived vascular modulatory cells to regulate tumor angiogenesis and invasion, Cancer Cell, 13, 206, 10.1016/j.ccr.2008.01.034 Nguyen, 2009, Metastasis: from dissemination to organ-specific colonization, Nat. Rev. Cancer, 9, 274, 10.1038/nrc2622 Wieser, 2005, Access of tumor-derived macromolecules and cells to the blood: an electron microscopical study of structural barriers in microvessel clusters in highly malignant primary prostate carcinomas, Prostate, 62, 123, 10.1002/pros.20129 Inai, 2004, Inhibition of vascular endothelial growth factor (VEGF) signaling in cancer causes loss of endothelial fenestrations, regression of tumor vessels, and appearance of basement membrane ghosts, Am. J. Pathol., 165, 35, 10.1016/S0002-9440(10)63273-7 Batchelor, 2007, AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients, Cancer Cell, 11, 83, 10.1016/j.ccr.2006.11.021 Jain, 2007, Effect of vascular normalization by antiangiogenic therapy on interstitial hypertension, peritumor edema, and lymphatic metastasis: insights from a mathematical model, Cancer Res., 67, 2729, 10.1158/0008-5472.CAN-06-4102 Xian, 2006, Pericytes limit tumor cell metastasis, J. Clin. Invest., 116, 642, 10.1172/JCI25705 Fidler, 2003, The pathogenesis of cancer metastasis: the ‘seed and soil’ hypothesis revisited, Nat. Rev. Cancer, 3, 453, 10.1038/nrc1098 Nikolova, 2007, The vascular niche and its basement membrane, Trends Cell Biol., 17, 19, 10.1016/j.tcb.2006.11.005 Hiratsuka, 2006, Tumour-mediated upregulation of chemoattractants and recruitment of myeloid cells predetermines lung metastasis, Nat. Cell Biol., 8, 1369, 10.1038/ncb1507 Psaila, 2009, The metastatic niche: adapting the foreign soil, Nat. Rev. Cancer, 9, 285, 10.1038/nrc2621 Kaplan, 2005, VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche, Nature, 438, 820, 10.1038/nature04186 Ebos, 2009, Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis, Cancer Cell, 15, 232, 10.1016/j.ccr.2009.01.021 Gao, 2008, Endothelial progenitor cells control the angiogenic switch in mouse lung metastasis, Science, 319, 195, 10.1126/science.1150224 Dawson, 2009, VEGFR1-activity-independent metastasis formation, Nature, 461, E4, 10.1038/nature08254 Kienast, Y. et al. (2010) Real-time imaging reveals the single steps of brain metastasis formation. Nat. Med. 16, 116–122 Fidler, 2002, Critical determinants of metastasis, Semin. Cancer Biol., 12, 89, 10.1006/scbi.2001.0416 Podsypanina, 2008, Seeding and propagation of untransformed mouse mammary cells in the lung, Science, 321, 1841, 10.1126/science.1161621 Kozlowski, 1984, Metastatic behavior of human tumor cell lines grown in the nude mouse, Cancer Res., 44, 3522 Warren, 1995, Regulation by vascular endothelial growth factor of human colon cancer tumorigenesis in a mouse model of experimental liver metastasis, J. Clin. Invest., 95, 1789, 10.1172/JCI117857 Schabel, 1977, Surgical adjuvant chemotherapy of metastatic murine tumors, Cancer, 40, 558, 10.1002/1097-0142(197707)40:1+<558::AID-CNCR2820400722>3.0.CO;2-K Tester, 2000, MMP-9 secretion and MMP-2 activation distinguish invasive and metastatic sublines of a mouse mammary carcinoma system showing epithelial-mesenchymal transition traits, Clin. Exp. Metastasis, 18, 553, 10.1023/A:1011953118186 Hirayama, 1984, Different metastatic modes of malignant melanoma implanted in the ear of young and old mice, Cancer Immunol. Immunother., 18, 209, 10.1007/BF00205513 Hoshida, 2006, Imaging steps of lymphatic metastasis reveals that vascular endothelial growth factor-C increases metastasis by increasing delivery of cancer cells to lymph nodes: therapeutic implications, Cancer Res., 66, 8065, 10.1158/0008-5472.CAN-06-1392 Schackert, 1989, Development of an animal model to study the biology of recurrent colorectal cancer originating from mesenteric lymph system metastases, Int. J. Cancer, 44, 177, 10.1002/ijc.2910440131 Takahashi, 1996, Progressive upregulation of metastasis-related genes in human colon cancer cells implanted into the cecum of nude mice, Oncol. Res., 8, 163 House, 1983, Clinical and in vivo response following surgery or surgery plus adjuvant chemotherapy or immunotherapy for colorectal carcinoma in a rat model, J. R. Soc. Med., 76, 833, 10.1177/014107688307601007 Singh, 2006, Using genetically engineered mouse models of cancer to aid drug development: an industry perspective, Clin. Cancer Res., 12, 5312, 10.1158/1078-0432.CCR-06-0437 McCart, 2008, Apc mice: models, modifiers and mutants, Pathol. Res. Pract., 204, 479, 10.1016/j.prp.2008.03.004 Lin, 2003, Progression to malignancy in the polyoma middle T oncoprotein mouse breast cancer model provides a reliable model for human diseases, Am. J. Pathol., 163, 2113, 10.1016/S0002-9440(10)63568-7 Guy, 1992, Expression of the neu protooncogene in the mammary epithelium of transgenic mice induces metastatic disease, Proc. Natl. Acad. Sci. U. S. A., 89, 10578, 10.1073/pnas.89.22.10578 Kouros-Mehr, 2008, GATA-3 links tumor differentiation and dissemination in a luminal breast cancer model, Cancer Cell, 13, 141, 10.1016/j.ccr.2008.01.011 Benson, 2009, Chemotherapy: adding oxaliplatin to the equation, Nat. Rev. Clin. Oncol., 6, 620, 10.1038/nrclinonc.2009.162 Ferrara N. (2009) Pathways mediating VEGF-independent tumor angiogenesis. Cytokine Growth Factor Rev., doi:10.1016/j.cytogfr.2009.11.003 Allegra, C. et al. (2009) Initial safety report of NSABP C-08: a randomized phase III study of modified FOLFOX6 with or without bevacizumab for the adjuvant treatment of patients with stage II or III colon cancer. J. Clin. Oncol. 27, 3385–3390 Paez-Ribes, 2009, Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis, Cancer Cell, 15, 220, 10.1016/j.ccr.2009.01.027 Stockmann, 2008, Deletion of vascular endothelial growth factor in myeloid cells accelerates tumorigenesis, Nature, 456, 814, 10.1038/nature07445